Professor Ashley Bush has been involved in metallobiology and neurodegeneration research since completing a PhD with Colin Masters (1992) and post-doctoral studies with Rudy Tanzi at Massachusetts General Hospital（MGH） (1992-4). The foundation of his laboratory's effort are the discoveries, made between 1992-1994, that the major proteins implicated in Alzheimer’s disease, Aβ and the amyloid protein precursor (APP), are metalloproteins whose properties are influenced by interaction with metal ions. This approach has lead to successful studies of novel chemotherapeutic agents in treating Alzheimer lesions in animal models, showing promise in Phase 2 clinical trials. Based upon their research into the biochemistry of AD, his laboratory has characterized several novel metal regulatory systems dysregulated in neurogeneration.